Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Posters

Search Title by author or title

Iontophoresis-assisted corneal cross-linking results in progressive keratoconus in an eye that previously underwent external beam radiotherapy and cryotherapies for retinoblastoma

Poster Details

First Author: E.Albe ITALY

Co Author(s):    P. Vinciguerra                    

Abstract Details

Purpose:

To show the mid-term effectiveness of iontophoresis-assised  corneal accelerated cross-linking in the right eye of a patient underwent to external beam radiotherapy and cryotherapies for heritable Retinoblastoma during infancy

Setting:

Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy

Methods:

A 26-year-old male presented with bilateral cortex and subcapsulr cataract in addition with a III stage keratoconus in both eyes. At birth he underwent in both eyes to external beam radiotherapy and cryotherapies for an heritable autosomal dominant retinoblastoma. Progression of keratoconus was documented in the right eye three months after the first visit by means of corneal topography and tomography. Corneal endothelial cell count, anterior and posterior segment optical coherence tomograpghy, UCVA , BSCVA, Corvis were assessed. Because of the previous external beam irradiation treatment, iontophoresis-assised  corneal accelerated cross-linking (10mW/cm2) was performed in his right eye.

Results:

Postoperative period was uneventful except an unexpected corneal de-epithelialization, which solved in two days with a bandage soft contact lens and standard postoperative treatment. Eighteen months after treatment the keratoconus is topographycally stable, the cornea clear, no deep stromal opacities were detected, no hyperopic shift and no reduction in UNCVA neither BSCVA were experienced by the patient.

Conclusions:

We reported a successful mid-term case of a iontophoresis-assised  corneal accelerated cross-linking in an eye previously irradiated and underwent to multiple cryotherapies for Retinoblastoma.

Financial Disclosure:

None

Back to Poster listing